157 related articles for article (PubMed ID: 30174794)
1. PD1 is expressed on exhausted T cells as well as virus specific memory CD8+ T cells in the bone marrow of myeloma patients.
Sponaas AM; Yang R; Rustad EH; Standal T; Thoresen AS; Dao Vo C; Waage A; Slørdahl TS; Børset M; Sundan A
Oncotarget; 2018 Aug; 9(62):32024-32035. PubMed ID: 30174794
[TBL] [Abstract][Full Text] [Related]
2. T cells in multiple myeloma display features of exhaustion and senescence at the tumor site.
Zelle-Rieser C; Thangavadivel S; Biedermann R; Brunner A; Stoitzner P; Willenbacher E; Greil R; Jöhrer K
J Hematol Oncol; 2016 Nov; 9(1):116. PubMed ID: 27809856
[TBL] [Abstract][Full Text] [Related]
3. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.
Atanackovic D; Cao Y; Luetkens T; Panse J; Faltz C; Arfsten J; Bartels K; Wolschke C; Eiermann T; Zander AR; Fehse B; Bokemeyer C; Kroger N
Haematologica; 2008 Mar; 93(3):423-30. PubMed ID: 18287134
[TBL] [Abstract][Full Text] [Related]
4. Variations in DNA methylation of interferon gamma and programmed death 1 in allograft rejection after kidney transplantation.
Boer K; de Wit LE; Peters FS; Hesselink DA; Hofland LJ; Betjes MG; Looman CW; Baan CC
Clin Epigenetics; 2016; 8():116. PubMed ID: 27891189
[TBL] [Abstract][Full Text] [Related]
5. Eomes Impedes Durable Response to Tumor Immunotherapy by Inhibiting Stemness, Tissue Residency, and Promoting the Dysfunctional State of Intratumoral CD8
Sun R; Wu Y; Zhou H; Wu Y; Yang Z; Gu Y; Jiang J; Lu B; Zhu Y
Front Cell Dev Biol; 2021; 9():640224. PubMed ID: 33553191
[TBL] [Abstract][Full Text] [Related]
6. Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma.
Schuberth PC; Jakka G; Jensen SM; Wadle A; Gautschi F; Haley D; Haile S; Mischo A; Held G; Thiel M; Tinguely M; Bifulco CB; Fox BA; Renner C; Petrausch U
Gene Ther; 2013 Apr; 20(4):386-95. PubMed ID: 22739387
[TBL] [Abstract][Full Text] [Related]
7. Quantitative and Qualitative Analysis of Bone Marrow CD8(+) T Cells from Different Bones Uncovers a Major Contribution of the Bone Marrow in the Vertebrae.
Geerman S; Hickson S; Brasser G; Pascutti MF; Nolte MA
Front Immunol; 2015; 6():660. PubMed ID: 26793197
[TBL] [Abstract][Full Text] [Related]
8. Global Pattern of CD8
Tian S; Wang F; Zhang R; Chen G
Front Pharmacol; 2021; 12():715721. PubMed ID: 34594218
[No Abstract] [Full Text] [Related]
9. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
10. Immune Phenotypes and Target Antigens of Clonally Expanded Bone Marrow T Cells in Treatment-Naïve Multiple Myeloma.
Welters C; Lammoglia Cobo MF; Stein CA; Hsu MT; Ben Hamza A; Penter L; Chen X; Buccitelli C; Popp O; Mertins P; Dietze K; Bullinger L; Moosmann A; Blanc E; Beule D; Gerbitz A; Strobel J; Hackstein H; Rahn HP; Dornmair K; Blankenstein T; Hansmann L
Cancer Immunol Res; 2022 Nov; 10(11):1407-1419. PubMed ID: 36122410
[TBL] [Abstract][Full Text] [Related]
11. BET inhibitors rescue anti-PD1 resistance by enhancing TCF7 accessibility in leukemia-derived terminally exhausted CD8
Romine KA; MacPherson K; Cho HJ; Kosaka Y; Flynn PA; Byrd KH; Coy JL; Newman MT; Pandita R; Loo CP; Scott J; Adey AC; Lind EF
Leukemia; 2023 Mar; 37(3):580-592. PubMed ID: 36681742
[TBL] [Abstract][Full Text] [Related]
12. A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1.
Ngiow SF; Young A; Jacquelot N; Yamazaki T; Enot D; Zitvogel L; Smyth MJ
Cancer Res; 2015 Sep; 75(18):3800-11. PubMed ID: 26208901
[TBL] [Abstract][Full Text] [Related]
13. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB
Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307
[TBL] [Abstract][Full Text] [Related]
14. Immune response to Moloney-murine leukemia virus-induced antigens in bone marrow.
Biasi G; Facchinetti A; Cappellari R; Rossi E; Zanovello P
Immunol Lett; 2011 Jul; 138(1):79-85. PubMed ID: 21453727
[TBL] [Abstract][Full Text] [Related]
15. [Molecular Profiles of Exhausted T Cells and Their Impact on Response to Immune Checkpoint Blockade].
Kagoya Y
Gan To Kagaku Ryoho; 2022 Jun; 49(6):609-614. PubMed ID: 35799382
[TBL] [Abstract][Full Text] [Related]
16. Coinhibitory Molecule PD-1 as a Therapeutic Target in the Microenvironment of Multiple Myeloma.
Atanackovic D; Luetkens T; Radhakrishnan S; Kroger N
Curr Cancer Drug Targets; 2017; 17(9):839-845. PubMed ID: 28875836
[TBL] [Abstract][Full Text] [Related]
17. Systemic and Terminal Ileum Mucosal Immunity Elicited by Oral Immunization With the Ty21a Typhoid Vaccine in Humans.
Booth JS; Patil SA; Ghazi L; Barnes R; Fraser CM; Fasano A; Greenwald BD; Sztein MB
Cell Mol Gastroenterol Hepatol; 2017 Nov; 4(3):419-437. PubMed ID: 29022005
[TBL] [Abstract][Full Text] [Related]
18. Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma.
Noonan KA; Huff CA; Davis J; Lemas MV; Fiorino S; Bitzan J; Ferguson A; Emerling A; Luznik L; Matsui W; Powell J; Fuchs E; Rosner GL; Epstein C; Rudraraju L; Ambinder RF; Jones RJ; Pardoll D; Borrello I
Sci Transl Med; 2015 May; 7(288):288ra78. PubMed ID: 25995224
[TBL] [Abstract][Full Text] [Related]
19. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.
Podar K; Jager D
Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977
[TBL] [Abstract][Full Text] [Related]
20. T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells.
Dhodapkar MV; Krasovsky J; Olson K
Proc Natl Acad Sci U S A; 2002 Oct; 99(20):13009-13. PubMed ID: 12235374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
